4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	461.60M +168.6%
Revenue (ttm)	88.24M +383,560.9%
Net Income	-160.90M
EPS	-2.64
Shares Out	52.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	560,414
Open	9.00
Previous Close	8.84
Day's Range	8.83 - 9.38
52-Week Range	3.68 - 12.34
Beta	2.76
Analysts	Buy
Price Target	28.22 (+219.59%)
Earnings Date	May 7, 2026

About Hemas Holdings

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2025, 4D Molecular Therapeutics's revenue was $85.21 million, an increase of 230194.59% compared to the previous year's $37,000. Losses were -$140.11 million, -12.90% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price target is $28.22, which is an increase of 219.59% from the latest price.

Price Target

$28.22

(219.59% upside)

Analyst Consensus: Buy